Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment

NCT03923478 is registered in ClinicalTrials.gov with Assembly Biosciences as lead sponsor.

NCT NCT03923478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03923478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment
Lead sponsor
Assembly Biosciences
Phase
Phase 1
Overall status
Terminated
Start date
June 24, 2019
Completion date
January 20, 2021
Enrollment
15 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis chronic mild, ulcerative colitis chronic moderate